Literature DB >> 9884485

Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients.

H K Jiang1, J Y Wang.   

Abstract

Although melatonin and/or cortisol secretions have been suggested as markers for both circadian and noradrenaline dysfunctions in psychiatric illnesses, especially in affective disorders, studies of melatonin and cortisol in schizophrenic patients are rare. We evaluated the circadian profiles of melatonin and cortisol secretion in schizophrenic patients and control subjects. A total of 21 medicated Taiwanese male paranoid schizophrenic inpatients (mean age, 27.3 +/- 7.2 yr) and 21 age- and sex-matched controls underwent 24-hour neuroendocrine screening. Melatonin and cortisol concentrations were measured at 2-hour intervals from 0800 h to 2200 h, and at 1-hour intervals from 2300 h to 0700 h. The standard dexamethasone suppression test was performed the next day to provide an index of hypothalamic-pituitary-adrenal axis (HPA) function. The results showed that the circadian rhythm of plasma melatonin secretion was disrupted in schizophrenics compared with controls, whereas the 24-hour profile of plasma cortisol was preserved. The melatonin to cortisol ratio was significantly higher in control subjects than in schizophrenic patients. Results of the dexamethasone suppression tests indicated that there were no functional changes in the HPA axis in schizophrenic patients. Five drug-naive schizophrenic patients studied simultaneously, but whose data were not included in the above analyses, had results consistent with those of the maintenance-medicated patients. Our findings suggest the presence of abnormal melatonin metabolism in Taiwanese schizophrenics, which may possibly be related to the pathophysiologic process itself. However, broader pathogenetic aspects of these neuroendocrine interrelations remain to be clarified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884485

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

1.  Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia.

Authors:  Cigdem Sahbaz; Omer Faruk Özer; Ayse Kurtulmus; Ismet Kırpınar; Fikrettin Sahin; Sinan Guloksuz
Journal:  Metab Brain Dis       Date:  2019-02-13       Impact factor: 3.584

Review 2.  Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects.

Authors:  George Anderson; Michael Maes
Journal:  Metab Brain Dis       Date:  2012-04-25       Impact factor: 3.584

3.  A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.

Authors:  H Y Chan; C J Chang; S C Chiang; J J Chen; C H Chen; H J Sun; H G Hwu; M S Lai
Journal:  J Psychopharmacol       Date:  2008-09-18       Impact factor: 4.153

4.  Quetiapine reduces nocturnal urinary cortisol excretion in healthy subjects.

Authors:  Stefan Cohrs; Kathrin Pohlmann; Zhenghua Guan; Wolfgang Jordan; Andreas Meier; Gerald Huether; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2004-01-20       Impact factor: 4.530

Review 5.  Role of melatonin in schizophrenia.

Authors:  Armando L Morera-Fumero; Pedro Abreu-Gonzalez
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.